{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T16:49:11Z","timestamp":1791132551255,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.antiviral.2012.09.006","type":"journal-article","created":{"date-parts":[[2012,9,19]],"date-time":"2012-09-19T09:30:28Z","timestamp":1348047028000},"page":"256-259","source":"Crossref","is-referenced-by-count":35,"title":["Are novel combination therapies needed for chronic hepatitis B?"],"prefix":"10.1016","volume":"96","author":[{"given":"Fabien","family":"Zoulim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2012.09.006_b0005","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1172\/JCI58847","article-title":"IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome","volume":"122","author":"Belloni","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.antiviral.2012.09.006_b0010","doi-asserted-by":"crossref","first-page":"19975","DOI":"10.1073\/pnas.0908365106","article-title":"Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function","volume":"106","author":"Belloni","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2012.09.006_b0230","series-title":"Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection","author":"Bertoletti","year":"2012"},{"key":"10.1016\/j.antiviral.2012.09.006_b0020","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.antiviral.2011.08.012","article-title":"The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication","volume":"92","author":"Billioud","year":"2011","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2012.09.006_b0025","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nm0598-610","article-title":"Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking","volume":"4","author":"Block","year":"1998","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2012.09.006_b0030","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1128\/AAC.00473-12","article-title":"Identification of the Disubstituted Sulfonamide Compounds as Specific Inhibitors of Hepatitis B Virus Covalently Closed Circular DNA Formation","volume":"56","author":"Cai","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2012.09.006_b0035","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1056\/NEJMe1113272","article-title":"A watershed moment in the treatment of hepatitis C","volume":"366","author":"Chung","year":"2012","journal-title":"The New England journal of medicine"},{"key":"10.1016\/j.antiviral.2012.09.006_b0225","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1128\/AAC.46.9.3057-3060.2002","article-title":"Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro","volume":"46","author":"Delaney","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2012.09.006_b0045","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1128\/AAC.46.2.425-433.2002","article-title":"Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro","volume":"46","author":"Delmas","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2012.09.006_b0050","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1126\/science.1077215","article-title":"Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids","volume":"299","author":"Deres","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2012.09.006_b0055","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMra0801644","article-title":"Hepatitis B virus infection","volume":"359","author":"Dienstag","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2012.09.006_b0060","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1002\/hep.23361","article-title":"Innate response to hepatitis B virus infection: observations challenging the concept of a stealth virus","volume":"50","author":"Durantel","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2012.09.006_b0065","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S1473-3099(11)70314-0","article-title":"Selection of chronic hepatitis B therapy with high barrier to resistance","volume":"12","author":"Gish","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2012.09.006_b0070","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1128\/JVI.62.11.4136-4143.1988","article-title":"Hepatitis B virus infection of adult human hepatocytes cultured in the presence of dimethyl sulfoxide","volume":"62","author":"Gripon","year":"1988","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2012.09.006_b0075","doi-asserted-by":"crossref","first-page":"15655","DOI":"10.1073\/pnas.232137699","article-title":"Infection of a human hepatoma cell line by hepatitis B virus","volume":"99","author":"Gripon","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2012.09.006_b0080","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.antiviral.2012.09.006_b0085","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2012-302085","article-title":"New perspectives in the therapy of chronic hepatitis B","volume":"61","author":"Lampertico","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.antiviral.2012.09.006_b0090","first-page":"S46","article-title":"Therapeutic efficacy of the TLR7 agonist GS-9620 for HBV chronic infection in chimpanzees","volume":"54","author":"Lanford","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2012.09.006_b0095","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.antiviral.2007.04.004","article-title":"Treatment of hepatitis B virus-infected cells with alpha-glucosidase inhibitors results in production of virions with altered molecular composition and infectivity","volume":"76","author":"Lazar","year":"2007","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2012.09.006_b0100","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1128\/AAC.44.1.111-122.2000","article-title":"Characterization of the antiviral effect of 2\u2019,3\u2019-dideoxy-2\u2019, 3\u2019-didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model","volume":"44","author":"Le Guerhier","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2012.09.006_b0105","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1128\/AAC.45.4.1065-1077.2001","article-title":"Antiviral activity of beta-L-2\u2019,3\u2019-dideoxy-2\u2019,3\u2019-didehydro-5-fluorocytidine in woodchucks chronically infected with woodchuck hepatitis virus","volume":"45","author":"Le Guerhier","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2012.09.006_b0110","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.3851\/IMP1679","article-title":"Evolution and suppression of HBV strains with multidrug resistance to lamivudine, adefovir dipivoxil and entecavir in a patient with chronic hepatitis B","volume":"15","author":"Liu","year":"2010","journal-title":"Antiviral therapy"},{"key":"10.1016\/j.antiviral.2012.09.006_b0115","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1053\/j.gastro.2012.05.037","article-title":"Efficacy of Entecavir With or Without Tenofovir Disoproxil Fumarate for Nucleos(t)ide-Naive Patients With Chronic Hepatitis B","volume":"143","author":"Lok","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2012.09.006_b0120","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.jhep.2011.02.015","article-title":"Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection","volume":"55","author":"Lucifora","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2012.09.006_b0125","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/hep.24758","article-title":"Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation","volume":"55","author":"Lutgehetmann","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2012.09.006_b0130","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nrd2411","article-title":"The way forward in HCV treatment\u2013finding the right path","volume":"6","author":"Manns","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.antiviral.2012.09.006_b0135","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B","volume":"351","author":"Marcellin","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2012.09.006_b0140","doi-asserted-by":"crossref","first-page":"8308","DOI":"10.1128\/JVI.00833-10","article-title":"Clonal expansion of normal-appearing human hepatocytes during chronic hepatitis B virus infection","volume":"84","author":"Mason","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2012.09.006_b0145","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jhep.2010.12.031","article-title":"Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges","volume":"54","author":"Michel","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2012.09.006_b0150","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nbt1389","article-title":"Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein","volume":"26","author":"Petersen","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.antiviral.2012.09.006_b0155","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jhep.2011.09.018","article-title":"Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study","volume":"56","author":"Petersen","year":"2012","journal-title":"J. Hepatol."},{"issue":"1360\u20131368","key":"10.1016\/j.antiviral.2012.09.006_b0160","first-page":"e1361","article-title":"Effectiveness of hepatitis B treatment in clinical practice","volume":"142","author":"Scaglione","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2012.09.006_b0165","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1128\/MMBR.64.1.51-68.2000","article-title":"Hepatitis B virus biology","volume":"64","author":"Seeger","year":"2000","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.antiviral.2012.09.006_b0170","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.antiviral.2011.07.003","article-title":"Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: a European multicenter study","volume":"92","author":"Si-Ahmed","year":"2011","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2012.09.006_b0175","doi-asserted-by":"crossref","first-page":"e8093","DOI":"10.1371\/journal.pone.0008093","article-title":"Mechanism for CCC DNA synthesis in hepadnaviruses","volume":"4","author":"Sohn","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.antiviral.2012.09.006_b0180","doi-asserted-by":"crossref","first-page":"11652","DOI":"10.1073\/pnas.1635109100","article-title":"Hepatocyte turnover during resolution of a transient hepadnaviral infection","volume":"100","author":"Summers","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"168\u2013176","key":"10.1016\/j.antiviral.2012.09.006_b0185","first-page":"e162","article-title":"In vitro characterization of viral fitness of therapy-resistant hepatitis B variants","volume":"136","author":"Villet","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2012.09.006_b0190","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1053\/j.gastro.2004.03.018","article-title":"Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy","volume":"126","author":"Werle-Lapostolle","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2012.09.006_b0195","doi-asserted-by":"crossref","first-page":"5660","DOI":"10.1021\/jm200696v","article-title":"Design, synthesis, and biological evaluation of triazolo-pyrimidine derivatives as novel inhibitors of hepatitis B virus surface antigen (HBsAg) secretion","volume":"54","author":"Yu","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2012.09.006_b0200","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jhep.2012.05.004","article-title":"Role of Toll-like receptor 2 in the immune response against hepadnaviral infection","volume":"57","author":"Zhang","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2012.09.006_b0205","doi-asserted-by":"crossref","first-page":"8013","DOI":"10.1128\/JVI.00366-08","article-title":"Zinc finger proteins designed to specifically target duck hepatitis B virus covalently closed circular DNA inhibit viral transcription in tissue culture","volume":"82","author":"Zimmerman","year":"2008","journal-title":"J. Virol."},{"issue":"1593\u20131608","key":"10.1016\/j.antiviral.2012.09.006_b0210","article-title":"Hepatitis B virus resistance to nucleos(t)ide analogues","volume":"137","author":"Zoulim","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2012.09.006_b0215","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/gutjnl-2011-300937","article-title":"Reasons to consider earlier treatment of chronic HBV infections","volume":"61","author":"Zoulim","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.antiviral.2012.09.006_b0220","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1128\/JVI.68.3.2026-2030.1994","article-title":"Woodchuck hepatitis virus X protein is required for viral infection in vivo","volume":"68","author":"Zoulim","year":"1994","journal-title":"J. Virol."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354212002033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354212002033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T00:13:21Z","timestamp":1594685601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354212002033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S0166354212002033"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2012.09.006","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}